Andy Plump, Takeda president of R&D (Jeff Rumans)
Takeda says TYK2 drug it purchased for $4B has passed another mid-stage test
Takeda announced Monday morning that the TYK2 inhibitor it bought from Nimbus Therapeutics for $4 billion has succeeded in a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
